The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: Description of methods of an interventional study designed to explore complex biologic problems

American Journal of Tropical Medicine and Hygiene

Volumn 92, Issue 4, 2015, Pages 744-751

  Kirkpatrick, Beth D ^a   Colgate, E Ross ^a   Mychaleckyj, Josyf C ^b   Haque, Rashidul ^c   Dickson, Dorothy M ^a   Carmolli, Marya P ^a   Nayak, Uma ^b   Taniuchi, Mami ^b   Naylor, Caitlin ^b   Qadri, Firdausi ^c   Ma, Jennie Z ^b   Alam, Masud ^c   Walsh, Mary Claire ^a   Diehl, Sean A ^a   Petri, William A ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE; ROTAVIRUS VACCINE; TRIVALENT INACTIVATED POLIO VACCINE; TRIVALENT ORAL POLIO VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ADULT; ARTICLE; BANGLADESH; DEVELOPING COUNTRY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLIOMYELITIS; ROTAVIRUS INFECTION; BLOOD; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; IMMUNOLOGY; INFANT; ORAL DRUG ADMINISTRATION; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; ROTAVIRUS INFECTIONS;

ROTAVIRUS;

ADMINISTRATION, ORAL; ANTIBODIES, VIRAL; BANGLADESH; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEVELOPING COUNTRIES; FEMALE; HUMANS; INFANT; MALE; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLIOVIRUS VACCINES; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 84926311433     PISSN: 00029637     EISSN: 14761645     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0518     Document Type: Article

References (22)

1. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, Mercado J, Gonzalez A, Malespin O, Amador JJ, Umaña J, Balmaseda A, Perez MC, Gentsch J, Kerin T, Hull J, Mijatovic S, Andrus J, Parashar U, 2009. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301: 2243-2251.
2. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, Neuzil KM, Ciarlet M, 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376: 615-623.
3. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study Team, 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354: 23-33.
4. CDC, 2010. Progress toward interruption of wild poliovirus transmission - worldwide, 2009. MMWR 59: 545-550.
5. CDC, 2009. Progress toward poliomyelitis eradication - India, January 2007-May 2009. MMWR 58: 719-723.
6. Korpe PPW, 2012. Environmental enteropathy: critical implications of a poorly understood condition. Trends Mol Med 18: 328-336.
7. Parashar UD, Glass RI, 2009. Rotavirus vaccines- early success, remaining questions. N Engl J Med 360: 1063-1065.
8. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI, 2009. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 200 (Suppl 1): S39-S48.
9. Mondal DMJ, Alam M, Liu Y, Dai J, Korpe P, Liu L, Haque R, Petri W, 2012. Contribution of enteric infection, altered intestinal barrier function, and maternal malnutrition to infant malnutrition in Bangladesh. Clin Infect Dis 42: 185-192.
10. Herremans TM, Reimerink JH, Buisman AM, Kimman TG, Koopmans MP, 1999. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 162: 5011-5018.
11. Grassly NC, Jafari H, Bahl S, Durrani S, Wenger J, Sutter RW, Aylward RB, 2009. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 200: 794-801.
12. Haque R, Snider C, Liu Y, Ma JZ, Liu L, Nayak U, Mychaleckyj JC, Korpe P, Mondal D, Kabir M, Alam M, Pallansch M, Oberste MS, Weldon W, Kirkpatrick BD, Petri WA Jr., 2014. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine 32: 478-482.
13. Available at: http://www.icddrb.org. 2014. Accessed August 8, 2014.
14. Available at: http://www.who.int/tdr/en/. Accessed August 8, 2014.
15. National Institute for Population Research and Training MaA, Macro International, 2009. Bangladesh Demographic and Health Survey 2007. Dhaka, Bangladesh and Calverton, MD.
16. Ballard JKK, Driver M, 1979. A simplified score for assessment of fetal maturation of newly born infants. J Pediatr 95: 769-774.
17. Azim T, Ahmad SM, Sefat EK, Sarker MS, Unicomb LE, De S, Hamadani JD, Salam MA, Wahed MA, Albert MJ, 1999. Immune response of children who develop persistent diarrhea following rotavirus infection. Clin Diagn Lab Immunol 6: 690-695.
18. World Health Organization, 2004. IVB Polio Laboratory Manual. Geneva, Switzerland: WHO.
19. World Health Organization, 1997. Manual for the Virological Investigation of Poliomyelitis. Geneva, Switzerland: WHO.
20. Galpin L, Manary MJ, Fleming K, Ou CN, Ashorn P, Shulman RJ, 2005. Effect of Lactobacillus GG on intestinal integrity in Malawian children at risk of tropical enteropathy. Am J Clin Nutr 82: 1040-1045.
21. Harrison JHRJ, Skully K, Lyman JA, 2011. Rapid development of research databases with Web access, flexible schemas, and linkage to local data resources. AMIA Summit on Clinical Research Informatics, San Francisco, CA.
22. th Annual Symposium on Biomedical and Health Informatics, Washington, DC, November 13-17, 2010.